Follow-Up Of Solitary Plasmacytoma By 99mtc-Sestamibi Scintigraphy(355 views) Catalano L, Andretta C, Pace L, Del Vecchio S, Fonti R, Pollio G, Salvatore B, Esposito C, Salvatore M, Rotoli B
Cattedra di Ematologia, Dip. Sc. Biomorfologiche/Funzionali, Universit Federico II, Napoli, Italy
Medicina Nucleare, Dip. Sc. Biomorfologiche/Funzionali, Universit Federico II, Napoli, Italy
Ist. di Biostrutture/Bioimmagini CNR, Castellammare di Stabia, Napoli, Italy
P. O. S. Leonardo ASL Napoli 5, Castellammare di Stabia, Napoli, Italy
Divisione di Ematologia Clinica, Cattedra di Ematologia, Universit Federico II, via S. Pansini 5, 80131 Napoli, Italy
P.O.S. Leonardo ASL Napoli 5, Castellammare di Stabia, Napoli, Italy
References: Ciu, M. L., Kronauge, J. F., Piwnica-Worms, D., Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-165
Del Vecchio, S., Ciarmiello, A., Salvatore, M., Clinical imaging of multidrug resistance in cancer (1999) Q J Nucl Med, 43, pp. 125-131
Kostkiewicz, M., Tracz, W., Przewlocki, T., Kawalec, E., Predictive potential of noninvasive methods, inclusive of exercise SPECT Tc99m MIBI imaging, in recognition of high-risk patients with left main coronary artery stenosis (2001) Int J Cardiovasc Imaging, 17, pp. 347-352
Hassan, I., Sahweil, A., Costantinides, C., Uptake and kinetics of tc-99m hexakis 2- methoxyisobutyl isonitrile in benign and malignant lesions in the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Caner, B., Kitapci, M., Aras, T., Increased accumulation of 2-methoxyisobutylisonitrile technetium in osteosarcoma and its metastatic lymph nodes (1991) J Nucl Med, 32, pp. 1977-1978
Kipatchi, M. T., Tastekin, G., Turgut, M., Preoperative localization of parathyroid carcinoma using 99mTc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C. H., Wang, S. J., Liu, T. J., The use of technetium-99m-methoxyisobutyl isonitrile brest scintigraphy to evalue palpable brest masses (1994) Eur J Nucl Med, 21, pp. 432-436
Wakasugi, S., Teshima, H., Nakamura, H., Tc-99m MIBI localization in bone marrow: A marker of bone marrow malignancy (1998) Clin Nucl Med, 23, pp. 664-671
Tirovola, E. B., Biassoni, L., Britton, K. E., The use of Tc-99m MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
Adams, B. K., Fataar, A., Nizami, M. A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Pace, L., Catalano, L., Del Vecchio, S., Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow up (2001) Eur J Nucl Med, 28, pp. 304-312
Balleari, E., Villa, G., Garre, S., Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease (2001) Haematologica, 86, pp. 78-84
Svaldi, M., Tappa, C., Gebert, U., Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation (2001) Ann Hematol, 80, pp. 393-397
Fonti, R., Del Vecchio, S., Zanetti, A., Bone marrow uptake of 99m Tc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) J Clin Oncol, 16, pp. 1677-1683
Knowling, M. A., Harwood, A. R., Bergsagel, D. E., Comparison of extramedullary plasmacytomas with solitary and multiple plasma cells tumors of bone (1983) J Clin Oncol, 1, pp. 255-262
Holland, J., Trenkner, D. A., Wasserman, T. H., Finegerg, B., Plasmacytoma (1991) Cancer, 69, pp. 1513-1517
Mayr, N. A., Wen, B. C., Hussey, D. H., The role of radiation therapy in the treatment of solitary plasmacytomas (1990) Radiother Oncol, 17, pp. 293-303
Hu, K., Yahalom, J., Radiotherapy in the management of plasma cell tumors (2000) Oncology, 14, pp. 101-108
Liebross, Rh., Ha, C. S., Cox, J. D., Clinical course of solitary extramedullary plasmacytoma (1999) Radiother Oncol, 52, pp. 245-249
Wilder, R. B., Ha, C. S., Cox, J. D., Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone (2002) Cancer, 94, pp. 1532-1537
Galieni, P., Cavo, M., Avvisati, G., Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two different entities? (1995) Ann Oncol, 6, pp. 687-691
Dimopoulos, M. A., Moulopoulos, A., Maniatis, A., Alexanian, R., Solitary plasmacytoma of bone and asymptomatic multiple myeloma (2000) Blood, 96, pp. 2037-2044
Jadvar, H., Conti, P. S., Diagnostic utility of FDG PET in multiple myeloma (2002) Skeletal Radiol, 31, pp. 690-694
Durie, B. G., Waxman, A. D., D'Agnolo, A., Williams, C. M., Whole-body (18) F-FDG PET identifies high risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Schirrmeister, H., Bommer, M., Buck, A., Initial results in the assessment of multiple myeloma using 8F-FDG PET (2002) Eur J Nucl Med, 29, pp. 361-366
Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy (1999) Haematologica, 84, pp. 119-124
Masini, L., Prosperi, D., Gamberi, B., Role of conventional skeletal X ray, Tc99-MDP scintigraphy and Tc99m-sestamibi in the detection of bone lesions in multiple myeloma (2002) Haematologica, (SUPPL. 87), p. 112. , abstract
Ciu, M.L., Kronauge, J.F., Piwnica-Worms, D., Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-165
Kipatchi, M.T., Tastekin, G., Turgut, M., Preoperative localization of parathyroid carcinoma using 99mTc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C.H., Wang, S.J., Liu, T.J., The use of technetium-99m-methoxyisobutyl isonitrile brest scintigraphy to evalue palpable brest masses (1994) Eur J Nucl Med, 21, pp. 432-436
Tirovola, E.B., Biassoni, L., Britton, K.E., The use of Tc-99m MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
Adams, B.K., Fataar, A., Nizami, M.A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Knowling, M.A., Harwood, A.R., Bergsagel, D.E., Comparison of extramedullary plasmacytomas with solitary and multiple plasma cells tumors of bone (1983) J Clin Oncol, 1, pp. 255-262
Mayr, N.A., Wen, B.C., Hussey, D.H., The role of radiation therapy in the treatment of solitary plasmacytomas (1990) Radiother Oncol, 17, pp. 293-303
Wilder, R.B., Ha, C.S., Cox, J.D., Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone (2002) Cancer, 94, pp. 1532-1537
Dimopoulos, M.A., Moulopoulos, A., Maniatis, A., Alexanian, R., Solitary plasmacytoma of bone and asymptomatic multiple myeloma (2000) Blood, 96, pp. 2037-2044
Durie, B.G., Waxman, A.D., D'Agnolo, A., Williams, C.M., Whole-body (18)F-FDG PET identifies high risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Follow-Up Of Solitary Plasmacytoma By 99mtc-Sestamibi Scintigraphy
Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80%. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.
Follow-Up Of Solitary Plasmacytoma By 99mtc-Sestamibi Scintigraphy
No results.
Follow-Up Of Solitary Plasmacytoma By 99mtc-Sestamibi Scintigraphy
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(731 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote